Paper Details

  1. Home
  2. Paper Details

First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.

Author: AndreasenLars V, DietrichJes, JustesenAnnette H, KromannIngrid, LindgrenLine M, NedergaardBettina S, OlsenKlaus J, SørensenCharlotte, Thierry-CarstensenBirgit, TingskovPernille N

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the immunogenicity and safety of three reduced dose IPV formulations adsorbed to aluminium hydroxide in Danish adolescents who were previously vaccinated with IPV. The study found that the three IPV-Al formulations were highly immunogenic, but inferior to IPV Vaccine SSI. The three IPV-Al SSI were also safe in adolescents and the booster effects were satisfactory.
Paper Details　
Original Abstract of the Article :
BACKGROUND: There is a demand of affordable IPV in the World. Statens Serum Institut (SSI) has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 IPV-Al, 1/5 IPV-Al and 1/10 IPV-Al SSI, and now report the results of the first investigations in humans. METHODS: 240 Da...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267481/

データ提供：米国国立医学図書館（NLM）

Exploring the Safety and Immunogenicity of Reduced Dose Inactivated Poliovirus Vaccines (IPV-Al SSI)

The quest for affordable and effective vaccines remains a constant pursuit. This [first-in-human safety and immunogenicity investigation] compares three reduced dose inactivated poliovirus vaccine formulations (IPV-Al SSI) to a full dose IPV Vaccine SSI in adolescents. The authors assess the booster effects and safety of these reduced dose formulations, seeking to identify potential cost-effective alternatives to the standard full dose vaccine.

Reduced Dose IPV-Al SSI: A Promising Alternative for Booster Vaccinations

The study's results demonstrate that the three reduced dose IPV-Al SSI formulations were [highly immunogenic] in adolescents, although they were [inferior to the full dose IPV Vaccine SSI] in terms of booster effects. The authors conclude that the three IPV-Al SSI formulations were safe, with [no serious adverse events] reported. The findings suggest that these reduced dose formulations could potentially serve as cost-effective alternatives for booster vaccinations, especially in resource-limited settings.

The Quest for Affordable and Effective Polio Vaccines

The quest for affordable and effective polio vaccines continues to be a priority. This study adds valuable data to the ongoing effort, suggesting that reduced dose IPV formulations could play a crucial role in expanding access to polio vaccination, particularly in regions where resources are limited. Further research and clinical trials are needed to confirm the long-term effectiveness and safety of these reduced dose formulations.

Dr. Camel's Conclusion

This study is like a well in the desert, providing a promising source of safe and effective polio vaccination. The results suggest that reduced dose IPV formulations could be a cost-effective solution for expanding polio vaccination coverage, especially in areas where resources are scarce. This research is a testament to the ongoing efforts to create a world where polio is eradicated.
Date :
  1. Date Completed 2017-12-15
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

28027810

DOI: Digital Object Identifier

PMC5267481

Related Literature

Article Analysis
・Side Effects of aluminum hydroxide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.